News | May 29, 2022
Venus Remedies registers 9.22 % growth in annual sales for FY22
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
Five patient-first principles to provide the highest standard of healthcare
The AI and technology upgrades allow doctors to choose their medical speciality and even spelling preferences to set their own speech model
The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
The new advanced regional processing lab will serve Nagpur city and the Vidarbha region
Subscribe To Our Newsletter & Stay Updated
